Compare BDJ & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BDJ | MESO |
|---|---|---|
| Founded | 2005 | 2004 |
| Country | United States | Australia |
| Employees | N/A | 81 |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | N/A | N/A |
| Metric | BDJ | MESO |
|---|---|---|
| Price | $9.73 | $16.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 581.4K | 215.0K |
| Earning Date | 01-01-0001 | 02-26-2026 |
| Dividend Yield | ★ 8.85% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $629.74 |
| Revenue Next Year | N/A | $30.65 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.42 | $11.05 |
| 52 Week High | $9.76 | $21.50 |
| Indicator | BDJ | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 68.88 | 68.30 |
| Support Level | $9.05 | $13.82 |
| Resistance Level | N/A | $17.33 |
| Average True Range (ATR) | 0.09 | 0.45 |
| MACD | 0.01 | 0.28 |
| Stochastic Oscillator | 100.00 | 98.40 |
BlackRock Enhanced Equity Dividend Trust is a closed-end management investment company. Its primary investment objective is to provide current income and current gains, with a secondary objective of long-term capital appreciation. The trust seeks to achieve its investment objectives by investing in common stocks that pay dividends and have the potential for capital appreciation and by utilizing an option to enhance distributions to its shareholders.
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.